Research progress of autoimmune glial fibrillary acidic protein astrocytopathy

Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever,...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	WANG Wen⁃wen [verfasserIn] LI Mei [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Chinesisch

Erschienen:	2022

Schlagwörter:	autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review

Übergeordnetes Werk:	In: Chinese Journal of Contemporary Neurology and Neurosurgery - Tianjin Huanhu Hospital, 2013, 22(2022), 3, Seite 205-210
Übergeordnetes Werk:	volume:22 ; year:2022 ; number:3 ; pages:205-210

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3969/j.issn.1672⁃6731.2022.03.014

Katalog-ID:	DOAJ006384269

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ006384269
003	DE-627
005	20230503072450.0
007	cr uuu---uuuuu
008	230225s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3969/j.issn.1672⁃6731.2022.03.014 \|2 doi
035			\|a (DE-627)DOAJ006384269
035			\|a (DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a chi
050		0	\|a RC346-429
100	0		\|a WANG Wen⁃wen \|e verfasserin \|4 aut
245	1	0	\|a Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.
650		4	\|a autoimmune diseases of the nervous system
650		4	\|a glial fibrillary acidic protein
650		4	\|a astrocytes
650		4	\|a review
653		0	\|a Neurology. Diseases of the nervous system
700	0		\|a LI Mei \|e verfasserin \|4 aut
773	0	8	\|i In \|t Chinese Journal of Contemporary Neurology and Neurosurgery \|d Tianjin Huanhu Hospital, 2013 \|g 22(2022), 3, Seite 205-210 \|w (DE-627)741171848 \|w (DE-600)2710763-2 \|x 16726731 \|7 nnns
773	1	8	\|g volume:22 \|g year:2022 \|g number:3 \|g pages:205-210
856	4	0	\|u https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569 \|z kostenfrei
856	4	0	\|u http://www.cjcnn.org/index.php/cjcnn/article/view/2476 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1672-6731 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 22 \|j 2022 \|e 3 \|h 205-210

Indexfelder

author_variant	w w ww l m lm
matchkey_str	article:16726731:2022----::eerhrgesfuomuelafbilraiip
hierarchy_sort_str	2022
callnumber-subject-code	RC
publishDate	2022
allfields	10.3969/j.issn.1672⁃6731.2022.03.014 doi (DE-627)DOAJ006384269 (DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569 DE-627 ger DE-627 rakwb eng chi RC346-429 WANG Wen⁃wen verfasserin aut Research progress of autoimmune glial fibrillary acidic protein astrocytopathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time. autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review Neurology. Diseases of the nervous system LI Mei verfasserin aut In Chinese Journal of Contemporary Neurology and Neurosurgery Tianjin Huanhu Hospital, 2013 22(2022), 3, Seite 205-210 (DE-627)741171848 (DE-600)2710763-2 16726731 nnns volume:22 year:2022 number:3 pages:205-210 https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014 kostenfrei https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569 kostenfrei http://www.cjcnn.org/index.php/cjcnn/article/view/2476 kostenfrei https://doaj.org/toc/1672-6731 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 3 205-210
spelling	10.3969/j.issn.1672⁃6731.2022.03.014 doi (DE-627)DOAJ006384269 (DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569 DE-627 ger DE-627 rakwb eng chi RC346-429 WANG Wen⁃wen verfasserin aut Research progress of autoimmune glial fibrillary acidic protein astrocytopathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time. autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review Neurology. Diseases of the nervous system LI Mei verfasserin aut In Chinese Journal of Contemporary Neurology and Neurosurgery Tianjin Huanhu Hospital, 2013 22(2022), 3, Seite 205-210 (DE-627)741171848 (DE-600)2710763-2 16726731 nnns volume:22 year:2022 number:3 pages:205-210 https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014 kostenfrei https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569 kostenfrei http://www.cjcnn.org/index.php/cjcnn/article/view/2476 kostenfrei https://doaj.org/toc/1672-6731 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 3 205-210
allfields_unstemmed	10.3969/j.issn.1672⁃6731.2022.03.014 doi (DE-627)DOAJ006384269 (DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569 DE-627 ger DE-627 rakwb eng chi RC346-429 WANG Wen⁃wen verfasserin aut Research progress of autoimmune glial fibrillary acidic protein astrocytopathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time. autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review Neurology. Diseases of the nervous system LI Mei verfasserin aut In Chinese Journal of Contemporary Neurology and Neurosurgery Tianjin Huanhu Hospital, 2013 22(2022), 3, Seite 205-210 (DE-627)741171848 (DE-600)2710763-2 16726731 nnns volume:22 year:2022 number:3 pages:205-210 https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014 kostenfrei https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569 kostenfrei http://www.cjcnn.org/index.php/cjcnn/article/view/2476 kostenfrei https://doaj.org/toc/1672-6731 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 3 205-210
allfieldsGer	10.3969/j.issn.1672⁃6731.2022.03.014 doi (DE-627)DOAJ006384269 (DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569 DE-627 ger DE-627 rakwb eng chi RC346-429 WANG Wen⁃wen verfasserin aut Research progress of autoimmune glial fibrillary acidic protein astrocytopathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time. autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review Neurology. Diseases of the nervous system LI Mei verfasserin aut In Chinese Journal of Contemporary Neurology and Neurosurgery Tianjin Huanhu Hospital, 2013 22(2022), 3, Seite 205-210 (DE-627)741171848 (DE-600)2710763-2 16726731 nnns volume:22 year:2022 number:3 pages:205-210 https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014 kostenfrei https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569 kostenfrei http://www.cjcnn.org/index.php/cjcnn/article/view/2476 kostenfrei https://doaj.org/toc/1672-6731 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 3 205-210
allfieldsSound	10.3969/j.issn.1672⁃6731.2022.03.014 doi (DE-627)DOAJ006384269 (DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569 DE-627 ger DE-627 rakwb eng chi RC346-429 WANG Wen⁃wen verfasserin aut Research progress of autoimmune glial fibrillary acidic protein astrocytopathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time. autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review Neurology. Diseases of the nervous system LI Mei verfasserin aut In Chinese Journal of Contemporary Neurology and Neurosurgery Tianjin Huanhu Hospital, 2013 22(2022), 3, Seite 205-210 (DE-627)741171848 (DE-600)2710763-2 16726731 nnns volume:22 year:2022 number:3 pages:205-210 https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014 kostenfrei https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569 kostenfrei http://www.cjcnn.org/index.php/cjcnn/article/view/2476 kostenfrei https://doaj.org/toc/1672-6731 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 3 205-210
language	English Chinese
source	In Chinese Journal of Contemporary Neurology and Neurosurgery 22(2022), 3, Seite 205-210 volume:22 year:2022 number:3 pages:205-210
sourceStr	In Chinese Journal of Contemporary Neurology and Neurosurgery 22(2022), 3, Seite 205-210 volume:22 year:2022 number:3 pages:205-210
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review Neurology. Diseases of the nervous system
isfreeaccess_bool	true
container_title	Chinese Journal of Contemporary Neurology and Neurosurgery
authorswithroles_txt_mv	WANG Wen⁃wen @@aut@@ LI Mei @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	741171848
id	DOAJ006384269
language_de	englisch chinesisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006384269</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503072450.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3969/j.issn.1672⁃6731.2022.03.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006384269</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC346-429</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">WANG Wen⁃wen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research progress of autoimmune glial fibrillary acidic protein astrocytopathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoimmune diseases of the nervous system</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glial fibrillary acidic protein</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">astrocytes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">review</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurology. Diseases of the nervous system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LI Mei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Chinese Journal of Contemporary Neurology and Neurosurgery</subfield><subfield code="d">Tianjin Huanhu Hospital, 2013</subfield><subfield code="g">22(2022), 3, Seite 205-210</subfield><subfield code="w">(DE-627)741171848</subfield><subfield code="w">(DE-600)2710763-2</subfield><subfield code="x">16726731</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:205-210</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.cjcnn.org/index.php/cjcnn/article/view/2476</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-6731</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">205-210</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	WANG Wen⁃wen
spellingShingle	WANG Wen⁃wen misc RC346-429 misc autoimmune diseases of the nervous system misc glial fibrillary acidic protein misc astrocytes misc review misc Neurology. Diseases of the nervous system Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
authorStr	WANG Wen⁃wen
ppnlink_with_tag_str_mv	@@773@@(DE-627)741171848
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC346-429
illustrated	Not Illustrated
issn	16726731
topic_title	RC346-429 Research progress of autoimmune glial fibrillary acidic protein astrocytopathy autoimmune diseases of the nervous system glial fibrillary acidic protein astrocytes review
topic	misc RC346-429 misc autoimmune diseases of the nervous system misc glial fibrillary acidic protein misc astrocytes misc review misc Neurology. Diseases of the nervous system
topic_unstemmed	misc RC346-429 misc autoimmune diseases of the nervous system misc glial fibrillary acidic protein misc astrocytes misc review misc Neurology. Diseases of the nervous system
topic_browse	misc RC346-429 misc autoimmune diseases of the nervous system misc glial fibrillary acidic protein misc astrocytes misc review misc Neurology. Diseases of the nervous system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Chinese Journal of Contemporary Neurology and Neurosurgery
hierarchy_parent_id	741171848
hierarchy_top_title	Chinese Journal of Contemporary Neurology and Neurosurgery
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)741171848 (DE-600)2710763-2
title	Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
ctrlnum	(DE-627)DOAJ006384269 (DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569
title_full	Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
author_sort	WANG Wen⁃wen
journal	Chinese Journal of Contemporary Neurology and Neurosurgery
journalStr	Chinese Journal of Contemporary Neurology and Neurosurgery
callnumber-first-code	R
lang_code	eng chi
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	205
author_browse	WANG Wen⁃wen LI Mei
container_volume	22
class	RC346-429
format_se	Elektronische Aufsätze
author-letter	WANG Wen⁃wen
doi_str_mv	10.3969/j.issn.1672⁃6731.2022.03.014
author2-role	verfasserin
title_sort	research progress of autoimmune glial fibrillary acidic protein astrocytopathy
callnumber	RC346-429
title_auth	Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
abstract	Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.
abstractGer	Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.
abstract_unstemmed	Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2014 GBV_ILN_2106 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
url	https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014 https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569 http://www.cjcnn.org/index.php/cjcnn/article/view/2476 https://doaj.org/toc/1672-6731
remote_bool	true
author2	LI Mei
author2Str	LI Mei
ppnlink	741171848
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3969/j.issn.1672⁃6731.2022.03.014
callnumber-a	RC346-429
up_date	2024-07-03T20:36:57.642Z
_version_	1803591632978706432
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006384269</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503072450.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3969/j.issn.1672⁃6731.2022.03.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006384269</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbee9bce7a2d14cb2815cfcc821cb1569</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC346-429</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">WANG Wen⁃wen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research progress of autoimmune glial fibrillary acidic protein astrocytopathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autoimmune diseases of the nervous system</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">glial fibrillary acidic protein</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">astrocytes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">review</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurology. Diseases of the nervous system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LI Mei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Chinese Journal of Contemporary Neurology and Neurosurgery</subfield><subfield code="d">Tianjin Huanhu Hospital, 2013</subfield><subfield code="g">22(2022), 3, Seite 205-210</subfield><subfield code="w">(DE-627)741171848</subfield><subfield code="w">(DE-600)2710763-2</subfield><subfield code="x">16726731</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:205-210</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3969/j.issn.1672⁃6731.2022.03.014</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bee9bce7a2d14cb2815cfcc821cb1569</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.cjcnn.org/index.php/cjcnn/article/view/2476</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-6731</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">205-210</subfield></datafield></record></collection>
score	7.4005775

Nicht das Richtige dabei?

Schreiben Sie uns!

Research progress of autoimmune glial fibrillary acidic protein astrocytopathy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?